Kyverna Therapeutics (KYTX) SEC Filings: History & Chart

Kyverna Therapeutics, Inc.(KYTX)

Biotechnology · Emeryville, CA

$6.39+0.07 (+1.11%)

Delayed quote: Oct 6, 2026, 11:10 AM EDT

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Emeryville, CA

149 employees

kyvernatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Warner Biddle

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 24, 2026	Sep 24, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
SC 13G	Jul 29, 2026	Jul 29, 2026	View filing
8-K	Jul 27, 2026	Jul 27, 2026	View filing
8-K	Jul 9, 2026	Jul 9, 2026	View filing
8-K	Jun 2, 2026	Jun 2, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 20, 2026	May 20, 2026	View filing
3	May 20, 2026	May 20, 2026	View filing
8-K	May 18, 2026	May 18, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
4	May 6, 2026	May 6, 2026	View filing
3	May 6, 2026	May 6, 2026	View filing
8-K	May 4, 2026	May 4, 2026	View filing
8-K	Apr 22, 2026	Apr 22, 2026	View filing
8-K	Apr 22, 2026	Apr 21, 2026	View filing
8-K	Apr 20, 2026	Apr 20, 2026	View filing
ARS	Apr 13, 2026	Apr 13, 2026	View filing
DEFA14A	Apr 13, 2026	Apr 13, 2026	View filing
DEF 14A	Apr 13, 2026	Apr 13, 2026	View filing
EFFECT	Apr 2, 2026	Apr 3, 2026	View filing
424B5	Apr 2, 2026	Apr 2, 2026	View filing
S-8	Mar 26, 2026	Mar 26, 2026	View filing

SEC Filings

Recent Filings